BlueWind Medical has closed $47.8 million in equity and debt financing to accelerate commercialization of the Revi System, an implantable tibial neuromodulation device for urgency urinary incontinence (UUI). The funding will support sales team expansion and broader market access initiatives.
Revi is implanted near the ankle in a single outpatient procedure under local anesthesia and delivers targeted stimulation to the posterior tibial nerve via a lightweight external wearable. Patients activate therapy once daily at home. Unlike other neuromodulation implants, Revi has no internal batteries or leads, avoiding complications like lead fracture, migration, or battery depletion.
The financing follows strong clinical data: Three-year results from the pivotal OASIS study confirmed sustained efficacy, excellent safety, and 95% patient satisfaction at 36 months.
“Urgency urinary incontinence affects millions of people, creating a significant need for effective, durable treatment options that fit seamlessly into patients’ lives,” said CEO Kerry Nelson. “This financing reflects deep conviction in our team, our technology, and the opportunity ahead to establish Revi as the new standard of care.”
UUI disproportionately affects women – particularly during and after menopause as hormonal changes impact bladder function.
